In an HCC study, levels of serum sFGL2 were reportedly higher in HCC patients [17], and hepatic stellate cells were found to secrete sFGL2 and inhibit the proliferation of CD8+ T cells, thereby hindering antitumor immunity [18]. Here, CD8A is linked to hepatocellular carcinoma.